Welcome to our dedicated page for Insight Molecular Diagnostics news (Ticker: IMDX), a resource for investors and traders seeking the latest updates and insights on Insight Molecular Diagnostics stock.
Insight Molecular Diagnostics Inc. reports developments for a molecular diagnostics business focused on donor-derived cell-free DNA testing for transplant monitoring. Its recurring updates cover the GraftAssure family of assays, including research-use and in vitro diagnostic kit development, kidney transplant rejection testing, clinical data presented in transplant and renal medicine forums, quality-system certification, and commercial preparation for localized organ health testing.
Company news also includes quarterly financial results, investor presentations, financing activity, partnerships supporting testing workflows, and regulatory activity for transplant diagnostic products.
iMDx (NASDAQ:IMDX) announced positive results from a head-to-head study comparing its GraftAssureIQ digital PCR-based test kit with NGS-based technology for kidney transplant rejection testing. The study, conducted at University Hospital Heidelberg, evaluated 96 kidney transplant recipients and demonstrated equivalent measurements between the two platforms in detecting donor-derived cell-free DNA (dd-cfDNA).
The company's digital PCR technology showed improved analytical sensitivity in detecting dd-cfDNA in low quantities. This data supports iMDx's preparation for commercial launch following expected regulatory approval in 2026, targeting the estimated $1 billion transplant rejection testing market. Extended study data will be presented at the upcoming European Society of Organ Transplantation Congress in London.